Nurtec ODT Shortage: What Providers and Prescribers Need to Know in 2026

Nurtec ODT (rimegepant) remains an important tool in the migraine treatment arsenal: the only FDA-approved oral medication for both acute treatment and prevention of episodic migraine. As of 2026, there is no formal FDA-listed shortage of Nurtec ODT. However, patient access difficulties are common and clinically relevant — and they require provider engagement to resolve.

This guide is designed for neurologists, headache specialists, PCPs, and other prescribers who regularly prescribe Nurtec ODT. It covers the current availability landscape, the insurance access hurdles your patients are navigating, clinical alternatives when Nurtec can't be obtained, and the Pfizer support resources your team should know about.

Current Availability Status: No FDA Shortage, But Access Barriers Persist

As of 2026, Nurtec ODT (rimegepant 75 mg ODT) is not listed on the FDA's Drug Shortages database. Pfizer (which acquired Biohaven in 2022) continues to manufacture and distribute rimegepant. The drug is available through major pharmaceutical wholesalers including McKesson, AmerisourceBergen, and Cardinal Health, and through most major pharmacy chains and mail-order services.

Despite stable manufacturing, your patients may still encounter prescription abandonment or delayed fills due to three primary barriers: prior authorization requirements, step therapy mandates, and the absence of a generic version keeping cash prices above $1,000 per pack.

Insurance Landscape for Nurtec ODT in 2026

According to the manufacturer, approximately 97% of commercially insured patients have some level of formulary coverage for Nurtec ODT. However, coverage doesn't mean unrestricted access:

Prior Authorization (PA): Required by the majority of commercial payers and most Medicare Part D plans. PA requests typically require documentation of diagnosis (episodic migraine with appropriate ICD-10 coding), treatment duration, and prior trial failure of triptans or contraindication to them.

Step Therapy: Many plans require documented failure of at least one oral triptan before approving a gepant. Documenting inadequate response, contraindications, or adverse effects with triptans is essential for PA approval.

Quantity Limits: Plans may limit coverage to a specific number of tablets per 30 days. For acute treatment, this is typically 8–16 tablets/month; for prevention (every other day dosing), 15 tablets/month is commonly needed.

Medicare/Medicaid: Nurtec is covered under some Medicare Part D plans but is not uniformly preferred. The Pfizer commercial copay card is not available to Medicare or Medicaid beneficiaries.

Optimizing Prior Authorization Documentation

A strong initial PA request reduces appeal burden for your team. Key elements to include:

Specific migraine diagnosis (G43.x ICD-10 codes; clarify episodic vs. chronic)

Headache days per month and impact on daily functioning (MIDAS or HIT-6 scores if available)

Triptan history: which ones tried, doses, duration, and reasons for failure (inadequate response, side effects, or contraindications — including cardiovascular disease, hemiplegic migraine, or pregnancy)

Clinical rationale for gepant use (CGRP pathway involvement, tolerability profile, dual acute/preventive use if applicable)

If prescribing for prevention: evidence of episodic migraine pattern (1–14 headache days/month) and any failure of prior preventives (topiramate, valproate, beta-blockers, antidepressants, or CGRP mAbs)

Clinical Alternatives When Nurtec ODT Cannot Be Obtained

When Nurtec ODT is inaccessible due to cost, coverage denial, or local availability, consider the following in-class and cross-class alternatives:

Ubrelvy (ubrogepant) 50–100 mg: Direct gepant alternative for acute treatment. Can be re-dosed once at 2 hours. AbbVie copay card available.

Qulipta (atogepant) 10/30/60 mg: Oral gepant for prevention of both episodic and chronic migraine. Daily oral tablet; slightly greater MMD reduction data than Nurtec in comparative analyses.

Zavzpret (zavegepant) nasal spray: Gepant nasal spray for acute treatment; useful for patients with prominent nausea or who prefer non-oral delivery.

CGRP mAbs (Aimovig, Ajovy, Emgality): Injectable preventives for patients with frequent episodic or chronic migraine. Better covered by Medicare in many cases than oral gepants.

Oral triptans: For acute treatment in patients without cardiovascular contraindications. Sumatriptan generics available for $5–$20 per 9-tablet course. Effective bridge while Nurtec access is being resolved.

Pfizer Support Resources for Providers

Your practice should be aware of the following Pfizer resources for patients who are struggling to access Nurtec:

Pfizer Migraine Patient Access Coordinators: Available at 866-222-4183. They can assist with PA navigation, formulary exceptions, and access support.

Bridge Benefit: One-time access to up to 16 tablets at no cost for eligible commercially insured patients while PA benefits are being verified.

Copay Card: Commercially insured patients may pay as little as $0/month (up to $7,000 annual benefit). Available at nurtec.com/savings.

Pfizer Patient Assistance Program: For uninsured or underinsured patients meeting income criteria (≤ ~$60,240/year single-person household), Nurtec ODT may be provided at no cost.

Office Samples: Contact your Pfizer medical science liaison or call 1-800-505-4426 to arrange sample delivery for your practice.

Incorporating Pharmacy Availability Tools Into Your Prescribing Workflow

When prescribing Nurtec ODT, consider recommending medfinder for providers to your patients. medfinder calls local pharmacies to check real-time Nurtec availability and texts results to the patient — reducing prescription abandonment from stock issues and saving your staff the time of troubleshooting pharmacy calls.

For a step-by-step clinical workflow guide, see how to help your patients find Nurtec ODT in stock.